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High Sustained Virologic Response Rates of Glecaprevir/
Pibrentasvir in Patients With Dosing Interruption or
Suboptimal Adherence
Philippe J. Zamor,MD1, Ashley Brown,MD2, Douglas E. Dylla, PhD3, John F. Dillon,MD4, Anne F. Luetkemeyer,MD5, Jordan J. Feld,MD6,
David Mutimer, MD7, Reem Ghalib, MD8, Eric Crown, PhD3, Sandra S. Lovell, PhD3, Yiran Hu, PhD3, Christophe Moreno, MD9,
David R. Nelson, MD10, Massimo Colombo, MD11, Georgios Papatheodoridis, MD, PhD12, Juergen K. Rockstroh, MD13,
Richard Skoien, MBBS, PhD14, Eric Lawitz, MD15 and Ira M. Jacobson, MD16
INTRODUCTION: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are
recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on
efficacy in patients with suboptimal adherence, particularly with shorter treatment durations. These
post hoc analyses evaluated adherence (based on pill count) in patients prescribed 8- or 12-week G/P,
the impact of nonadherence on sustained virologic response at post-treatment week 12 (SVR12),
factors associated with nonadherence, and efficacy in patients interrupting G/P treatment.
METHODS: Data were pooled from 10 phase 3 clinical trials of treatment-naive patients with HCV genotype 1–6
without cirrhosis/with compensated cirrhosis (treatment adherence analysis) and 13 phase 3 clinical
trials of all patients with HCV (interruption analysis).
RESULTS: Among 2,149 patients included, overall mean adherence was 99.4%. Over the treatment duration,
adherence decreased (weeks 0–4: 100%; weeks 5–8: 98.3%; and weeks 9–12: 97.1%) and the
percentage of patients with ‡80% or ‡90% adherence declined. SVR12 rate in the intention-to-treat
(ITT) population was 97.7% (modified ITT SVR12 99.3%) and remained high in nonadherent patients
in the modified ITT population (<90%: 94.4%–100%; <80%: 83.3%–100%). Psychiatric disorders
were associated with <80% adherence, and shorter treatment duration was associated with ‡80%
adherence. Among 2,902 patients in the interruption analysis, 33 (1.1%) had a G/P treatment
interruption of ‡1 day, with an SVR12 rate of 93.9% (31/33). No virologic failures occurred.
DISCUSSION: These findings support the impact of treatment duration on adherence rates and further reinforce the
concept of “treatment forgiveness” with direct-acting antivirals.
SUPPLEMENTARYMATERIAL accompanies this paper at http://links.lww.com/AJG/C43, http://links.lww.com/AJG/C44, http://links.lww.com/AJG/C45, http://links.lww.
com/AJG/C46, and http://links.lww.com/AJG/C47
Am J Gastroenterol 2021;116:1896–1904. https://doi.org/10.14309/ajg.0000000000001332
INTRODUCTION
The advent of highly curative treatments for hepatitis C virus
(HCV) infectionhas transformed the treatment landscape forHCV.
Pangenotypic, all-oral, interferon-free direct-acting antivirals
(DAAs), including the 2-drug combinations of glecaprevir/
pibrentasvir (G/P) and sofosbuvir/velpatasvir (SOF/VEL), are well
tolerated and highly effective with relatively short treatment dura-
tions (1,2).However, despite these developments, it is estimated that
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most people living with HCV are unaware of their diagnosis, and
only a minority of those aware are receiving treatment (3). Fur-
thermore, historical concerns over nonadherence and its possible
clinical impact endure from the pre-DAA era (4).
The underlying concerns regarding DAA nonadherence are
increased risk of treatment failure and the emergence of
resistance-associated substitutions that may make retreatment
difficult (5-7) and hence may deter healthcare professionals from
prescribing treatment for some patients (8-11). Indeed, recent
evidence suggests substance use, alcohol use, and unstable
housing are still perceived by treatment providers as barriers to
adherence (5,12,13). Although it is acknowledged that treatment
in some patient populations remains challenging, there is an
emergent consensus that drug use should not be considered an
contraindication for HCV treatment by clinicians or insurance
payers (14).
In addition to the proven efficacy of pangenotypic, all-oral
DAAs, high adherence has been observed in patients at risk of
poor adherence, including those with mental health conditions
and substance use (6,7,15). Nevertheless, adherence to DAAs has
been demonstrated to decline steadily over the course of treat-
ment (6,8,16,17). For this reason, shorter treatment durations
that do not compromise sustained virologic response (SVR) rates
may positively impact adherence, especially for patients who are
less engaged in healthcare. Short HCV treatment duration,
therefore, may be a key component to facilitate progress toward
theWorldHealth Organization goal to eliminate HCV as amajor
public health threat by 2030 (18).
G/P is approved to treat patients aged 12 years and older who
are chronically infected with HCV genotypes (GT)1–6. High
SVR12 rates were observed with the shortest approved treatment
duration of 8 weeks for patients without cirrhosis and treatment-
naive patients with compensated cirrhosis (1). Clinical trials and
real-world studies of G/P have demonstrated low rates of dis-
continuation and high rates of adherence (1,19–21). With most
HCV-infected patients eligible for 8-week G/P treatment, con-
cerns have been raised as to whether suboptimal adherence or
treatment interruption could negatively impact SVR12 rates,
given its short treatment duration. For this reason, the “clinical
forgiveness” (i.e., the ability of effective treatment to be unaffected
by suboptimal treatment adherence) of the 8-week G/P regimen
requires further investigation. In the current post hoc analyses, we
assessed the impact of treatment duration on adherence in pa-
tients prescribed 8 or 12 weeks of G/P, the factors associated with
nonadherence, and the impact of nonadherence on SVR12. In
addition, we investigated efficacy outcomes in patients inter-
rupting G/P treatment.
METHODS
Study design and patient population
These analyses included patients from a total of 13 phase 3 clinical
trials, with data from 10 studies used for the treatment adherence
analysis and data from 13 studies used for the treatment in-
terruption analysis. For all included studies, written informed
consent was obtained from each patient and the study protocol
conformed to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the appropriate in-
stitutional review committee.
Treatment adherence analysis. Data were pooled from 10 phase 3
clinical trials of treatment-naive patients with HCV GT1–6, without
cirrhosis or with compensated cirrhosis, prescribed 8- or 12-week
G/P treatment regimens. These were SURVEYOR-2 (part 3 and part
4; NCT02243293) (22,23), ENDURANCE-1 (NCT02604017) (24),
ENDURANCE-2 (active arm;NCT02640482) (23), ENDURANCE-
3 (NCT02640157) (24), ENDURANCE-4 (NCT02636595) (23),
ENDURANCE-5,6 (NCT02966795) (25), the aspartate amino-
transferase-to-platelet ratio index (APRI) study (NCT03212521)
(26), EXPEDITION-1 (NCT02642432) (27), EXPEDITION-2
(NCT02738138) (28), and EXPEDITION-8 (NCT03089944) (29).
The inclusion and exclusion criteria for each study have been
previously reported (22–29). In brief, patients were aged 18 years
and older, with chronic HCV GT1–6 infection with or without
compensated cirrhosis. Patients with coinfection of multiple
HCV genotypes were excluded in all studies, except the APRI
study. Patients with a positive test for hepatitis B surface antigen
were excluded. Patients in EXPEDITION-2 were coinfected with
human immunodeficiency virus (HIV)-1 (28); patients with
HIV-1 coinfection were also eligible for ENDURANCE-1 (24)
and the APRI study (26), but not for the other studies. To be
included in this analysis, patients were required to have an
intended treatment duration of 8 or 12 weeks.
Only trial data from patients naive to newer DAA treatment
(such as G/P and SOF/VEL) or those experienced with interferon
or pegylated interferon treatment with or without ribavirin, or
SOF plus ribavirin with or without pegylated interferon were
included in this analysis to avoid biases related to previous
treatment experience on subsequent outcomes, including rates of
adherence and interruption.
Treatment interruption analysis. Data were pooled from 13
phase 3 clinical trials for all patients with HCVwho completed 8-
or 12-weekG/P treatment ($52 days of treatment for 8-weekG/P
and $77 days of treatment for 12-week G/P). These were
SURVEYOR-2 (part 3 and part 4; NCT02243293) (22,23),
ENDURANCE-1 (NCT02604017) (24), ENDURANCE-2 (active
arm; NCT02640482) (23), ENDURANCE-3 (NCT02640157)
(24), ENDURANCE-4 (NCT02636595) (23), ENDURANCE-5,6
(NCT02966795) (25), the APRI study (NCT03212521) (26),
EXPEDITION-1 (NCT02642432) (27), EXPEDITION-2
(NCT02738138) (28), EXPEDITION-4 (NCT02651194) (30),
EXPEDITION-5 (NCT03069365) (31), EXPEDITION-8
(NCT03089944) (29), andMAGELLAN-2 (NCT02692703) (32).
The inclusion and exclusion criteria for each study have been
previously reported (22–32). In addition to those stated above,
patients in EXPEDITION-4 had chronic kidney disease stage 4 or
5 (30); patients in EXPEDITION-5 had chronic kidney disease
stage 3b, 4, or 5 (31). Patients inMAGELLAN-2were recipients of
kidney or liver transplants (32). No specific exclusion criteria
were applied to this post hoc analysis, and therefore, patients naive
to HCV treatment or experienced to pegylated interferon plus
ribavirin (with or without SOF) were included.
Endpoints and assessments
Treatment adherence analysis. Adherence was calculated using
available data on the percentage of pills taken relative to total
number expected to be taken during each dispensation interval
(weeks 0–4, weeks 5–8, and weeks 9–12), excluding any patient
with missing pill count data for that interval. Electronic detection
of bottle opening as a pill countmethodwas not used in the study,
and missing pill count data are reported in the results. Drug
accountability was performed by the monitor throughout the
treatment period. Final accountability was verified by the monitor
on the completion of or discontinuation of the study drug
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treatment at the site. SVR12 was assessed in the intention-to-treat
(ITT) population (all patients receiving $1 dose of G/P) and the
modified ITT population, which excluded those who did not
achieve SVR12 because of nonvirologic failure, including
premature treatment discontinuation, reinfection, and missing
SVR12 data.
Treatment interruption analysis. Treatment interruption was
defined as a temporary stop in G/P treatment for $1 day.
Table 1. Demographics and clinical characteristics at baseline
Adherence Interruption
Overall (N 5 2,149)
Patients with
interruption;
8 wks (N 5 17)
Patients with
interruption;
12 wks (N 5 16)
Total population with and without
interruption (N 5 2,902)
Male 1,163 (54.1) 9 (52.9) 9 (56.3) 1,652 (56.9)
Age $65 yr 299 (13.9) 5 (29.4) 2 (12.5) 461 (15.9)
Race
White 1,733 (80.7) 14 (82.4) 13 (81.3) 2,287 (78.9)
Black/African American 129 (6.0) 2 (11.8) 1 (6.3) 192 (6.6)
Asian 251 (11.7) 1 (5.9) 2 (12.5) 372 (12.8)
Other 35 (1.6) 0 0 48 (1.7)
Missing 1 0 0 3
BMI $30 kg/m2 451 (21.0) 5 (29.4) 4 (25.0) 606 (20.9)
Missing 1 0 0 1
HCV RNA $6,000,000 log10
IU/mL
454 (21.1) 4 (23.5) 2 (12.5) 581 (20.0)
HCV GT
1 962 (44.8) 14 (82.4) 6 (37.5) 1,431 (49.3)
2 357 (16.6) 2 (11.8) 6 (37.5) 492 (17.0)
3 554 (25.8) 1 (5.9) 2 (12.5) 610 (21.0)
4/5/6 130 (6.0)/44 (2.0)/102
(4.7)
0/0/0 2 (12.5)/0/0 202 (7.0)/54 (1.9)/113 (3.9)
Previous HCV treatment experience NA 1 (5.9) 2 (12.5) 576 (19.8)
Compensated cirrhosis 515 (24.0) 7 (41.2) 5 (31.3) 579 (20.0)
Fibrosis stagea
F0–F1 1,184 (61.8) 2 (22.2) 11 (68.8) 1,717 (64.3)
F2 81 (4.2) 0 1 (6.3) 134 (5.0)
F3 136 (7.1) 0 0 242 (9.1)
F4 515 (26.9) 7 (77.8) 4 (25.0) 577 (21.6)
Missing 233 0 0 6
Comorbidities
History of injection drug use 856 (39.8) 7 (41.2) 6 (37.5) 1,023 (35.3)
On stable OAT 183 (8.5) NR NR NR
Current alcohol use 726 (33.8) 8 (47.1) 6 (37.5) 905 (31.2)
History of psychiatric disorder 606 (28.2) NR NR NR
History of depression or bipolar
disorder
NR 3 (17.6) 2 (12.5) 503 (17.3)
Presence of polypharmacyb 586 (27.3) NR NR NR
Data are n (%) unless stated otherwise; percentages calculated based on nonmissing values.
APRI, aspartate aminotransferase-to-platelet ratio index; BMI, body mass index; GT, genotype; HCV, hepatitis C virus; NA, not applicable; NR, not reported; OAT, opioid
agonist therapy.
aBaseline fibrosis stage was not collected in the APRI study.
bPolypharmacy is defined by$5 concomitant medications.





Duration of interruption was calculated as the total number of
days of interruption for each patient who temporarily stopped
dosing and went on to complete treatment. Premature treatment
discontinuation was defined as any patient who stopped treat-
ment before the completion of the therapy and did not restart
treatment. The rate of SVR12 was determined in the ITT pop-
ulation comprising all patients who received $1 dose of G/P.
Statistical analysis
Adherence and interruption data were summarized descriptively.
Meanadherence rates and theproportionsof patientswhowere$80%
and $90% adherent were reported. In addition, median (range)
number of treatment interruptions and duration were reported. Ad-
herence rates were compared between treatment intervals, and the
statistical significance was determined using 2-sample z tests (33).
Stepwise logistic regression analyses with significance level of
0.1 for entering effects and 0.1 for removing effects were used to
identify factors associated with nonadherence during any time
interval. The regression model included independent categorical
covariates of treatment duration (8 or 12 weeks), cirrhosis status
(nocirrhosis or compensated cirrhosis), sex (male or female), Black
race (yes or no), Hispanic/Latino (yes or no), geographic region
(Europe, North America, or rest of the world), stable opioid
agonist therapy (yes or no), history of injection drug use (yes or
no), presence of polypharmacy defined as using $5 concomi-
tant medications (yes or no), current tobacco use (yes or no),
current alcohol use (yes or no), history of psychiatric disorder
(yes or no), HIV-1 coinfection (yes or no), andHCVGT (GT1 vs
each GT2–6), and continuous covariates of age (year), body
mass index (kg/m2), and baseline HCV RNA (log10 IU/mL).
RESULTS
Patient characteristics
Treatment adherence analysis population. Among all 2,149
patients included in the treatment adherence analysis, median
(range) age was 53.0 (19–88) years, 54.1% were men, 27.3% were
receiving polypharmacy, and 39.8% had a history of injection
drug use (Table 1). Among 1,634 (76.0%) patients without cir-
rhosis, 58.8% received 8-week treatment, and among 515 (24.0%)
patients with compensated cirrhosis, 66.6% received 8-week
treatment. Baseline demographics and clinical characteristics by
cirrhosis status and treatment duration are provided in Supple-
mentary Table (see SupplementaryDigital Content 1, http://links.
lww.com/AJG/C43); 1,304 and 845 patients were treated for 8 and
12 weeks, respectively.
Treatment interruption analysis population. Among 2,902 pa-
tients included in the treatment interruption analysis, 33 (1.1%)
had a G/P treatment interruption $1 day and went on to com-
plete treatment; 17 patients received 8-week treatment, and 16
patients received 12-week treatment. Baseline demographics and
disease characteristics of the patients in the treatment in-
terruption analysis population are shown in Table 1. Among the
patients who had a G/P treatment interruption, 21.2% were aged
65 years and older, 54.5% were men, 36.4% had compensated
cirrhosis, 39.4% had a history of injection drug use, and 90.9%
were HCV treatment–naive.
Treatment adherence
Overall, 9.9% (207/2,107) of patients were nonadherent for $1
4-week interval. Mean treatment adherence for the overall treat-
ment period was 99.4%. Adherence decreased as treatment length
increased; mean adherence was 100% for weeks 0–4, 98.3% for
weeks 5–8, and97.1% forweeks 9–12 (Figure 1). Similar downward
trends in mean adherence were seen over the 4-week intervals
regardless of treatment duration or baseline cirrhosis status (see
Supplementary Figure, Supplementary Digital Content 2, http://
links.lww.com/AJG/C44). For the overall population, the per-
centage of patients with$80% or$90% adherence declined over
time (Figure 2) and did not differ by treatment duration or baseline
cirrhosis status (see Supplementary Figure, Supplementary Digital
Content 3, http://links.lww.com/AJG/C45). Comparing weeks 5–8
with weeks 0–4, the odds ratio (OR) was 2.59 (95% confidence
interval [CI] 1.29–5.20; P5 0.007) for,80% adherence and 3.74
(95% CI 2.50–5.58; P, 0.0001) for,90% adherence. Comparing
weeks 9–12 with weeks 5–8, the OR was 1.86 (95%CI 1.05–3.28; P
5 0.033) for ,80% adherence and 1.68 (95% CI 1.24–2.29; P ,
0.001) for,90% adherence.
Figure 1.Mean adherence by treatment interval.
Figure 2. Percentage of patients with $80% or $90% adherence by
treatment interval. Missing: n5 149, weeks 0–4; n5 97, weeks 5–8; and
n 5 1,339, weeks 9–12.
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In total, there were missing pill count data for 148/2,149 (7%)
patients during weeks 0–4, 97/2,149 (4.5%) patients during weeks
5–8, and 35/845 (4.1%) during weeks 9–12. No patient with
missing pill count data failed treatment.
SVR12 in treatment adherence analysis population. Overall,
SVR12 in the ITT population was 97.7% (2,100/2,149; 95% CI
97.0–98.3); SVR12 in the modified ITT population was 99.3%
(2,100/2,114; 95% CI 98.9–99.6). For patients with $90% ad-
herence in the modified ITT population, SVR12 rates ranged
from 99.3% to 99.7% for all treatment intervals, regardless of
treatment duration or cirrhosis status (see Supplementary
Figure, Supplementary Digital Content 4A, http://links.lww.
com/AJG/C46). SVR12 rates of nonadherent patients in the
modified ITT population were also universally high regardless
of level of nonadherence (,90%: 94.4%–100%; ,80%:
83.3%–100%). SVR12 was achieved in all but 4 patients with-
out cirrhosis receiving G/P for 12 weeks and all but 2 patients
with compensated cirrhosis receiving G/P for 12 weeks (see
Supplementary Figure, Supplementary Digital Content 4,
http://links.lww.com/AJG/C46). No patient who was non-
adherent (,90%) to the 8-week regimen of G/P (n 5 3) ex-
perienced virologic failure.
Among those treated for 8 weeks, 2 patients (0.2%) had
80%–90% adherence and 1 (0.1%) had ,80% adherence during
both 4-week intervals but all achieved SVR12. In the 12-week
treatment group, 5 patients (0.6%) had 80%–90% adherence and
2 patients (0.2%) had ,80% adherence during $2 4-week in-
tervals but all achieved SVR12.
Predictors of nonadherence. Psychiatric disorders were associ-
ated with ,80% adherence (OR 2.57, 95% CI 1.52–4.35), and
shorter treatment duration was associated with$80% adherence
(OR 0.59, 95% CI 0.35–0.99) (Table 2). Ten baseline factors were
statistically predictive of,90% nonadherence, with the strongest
predictors being 8- vs 12-week treatment duration (OR 0.52, 95%
CI 0.38–0.71), age in years (OR 0.98, 95%CI 0.97–0.99), and GT6
vs GT1 infection (OR 2.41, 95% CI 1.29–4.49).
Treatment interruption
Overall, 1.2% (33/2,839) of patients experienced a treatment in-
terruption of $1 day. Among patients with G/P treatment
interruption, the median number of days for interruption was 2
(8-weekG/P range 1–6; 12-weekG/P range 1–62). Treatmentwas
interrupted for#2 days in 23/33 (69.7%) of patients, 3–7 days in 9
patients (27.3%), and 1 patient (3.0%) with 4 interruptions to-
taling 62 days.
Figure 3 provides the timing, duration, and reason for each
G/P treatment interruption. G/P was interrupted on multiple
occasions by 4 patients. The most frequently reported reason for
G/P treatment interruption was an adverse event, occurring
in 16/33 patients (48.5%; 8-week G/P: 6/17 patients [35.3%];
12-week G/P: 10/16 patients [62.5%]). Missed dose was the sec-
ond most common reason for interruption occurring in 14/33
patients (42.4%; 8-weekG/P: 9/17 patients [52.9%]; 12-weekG/P:
5/16 patients [31.3%]). One patient with 4 treatment interrup-
tions totaling 62 days of a planned 84-day G/P course stopped
taking the medication in between study visits without telling
Table 2. Predictors of nonadherence
Variable Odds ratio (95% CI) P
,80% adherencea
History of psychiatric disorder (yes vs no) 2.57 (1.52–4.35) ,0.001
Treatment duration (12 vs 8 wk) 1.71 (1.01–2.89) 0.046
,90% adherenceb
Treatment duration (12 vs 8 wk) 1.93 (1.42–2.63) ,0.001
Age, yr 0.98 (0.97–0.99) 0.002
HCV GT6 vs GT1 2.41 (1.29–4.49) 0.006
Geographic region (North America vs
Europe)
1.57 (1.09–2.27) 0.016
Sex (male vs female) 1.46 (1.07–2.00) 0.016
History of psychiatric disorder (yes vs no) 1.50 (1.07–2.10) 0.020
Black race (yes vs no) 1.81 (1.04–3.14) 0.035
Presence of polypharmacyc (yes vs no) 1.46 (1.02–2.08) 0.037
HCV GT3 vs GT1 1.48 (1.02–2.14) 0.040
HIV-1–coinfected (yes vs no) 1.70 (1.01–2.87) 0.048
Patients missing any independent variables were excluded from analyses. Outcomes were nonadherence (,80% or ,90%) during any time interval.
CI, confidence interval; GT, genotype; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus 1; RNA, ribonucleic acid.
aVariables included in the stepwise logistic regression model with a P value .0.05: age. Variables examined but not selected by the stepwise logistic regression model
included cirrhosis status; sex; race; ethnicity; body mass index (kg/m2); geographic region; stable opioid agonist therapy; injection drug use; polypharmacy use; tobacco
use; alcohol use; HCV GT; baseline HCV RNA level (log10 IU/mL); and HIV-1 coinfection.
bVariables included in the stepwise logistic regression model with a P value.0.05: ethnicity; geographic region (North America vs rest of world); and HCV GT2, 4, and 5.
Variables examined but not selected by the stepwise logistic regression model included cirrhosis status; body mass index (kg/m2); stable opioid agonist therapy; injection
drug use; tobacco use; alcohol use; and baseline HCV RNA level (log10 IU/mL).
cPolypharmacy was defined as$5 concomitant medications.





anyone because he “thought he was on placebo”; this patient
achieved SVR12 despite only taking 22 days of treatment.
SVR12 in patients with G/P treatment interruption. The overall
SVR12 rate was 93.9% in patients interrupting 8- or 12-week G/P
treatment (8-week G/P: 16/17 [95% CI 73.0–99.0]; 12-week G/P:
15/16 [95% CI 71.7–98.9]). No virologic failures occurred, and 2
patients had missing SVR12 data. One of the patients with non-
virologic failure missed a dose for 1 day and the other interrupted
treatment for 5 days between days 55 and 59 of the 12-week
treatment because of aspiration pneumonia, which was consid-
ered not related to DAA administration; this patient died of an
unknown cause on post-treatment day 14.
SVR12 in patients with premature G/P treatment discontinuation.
A total of 38 patients prematurely discontinued treatment (8-
week G/P: median treatment duration of 17 days [range 2–49
days]; 12-week G/P: median treatment duration of 50 days
[range 5–83 days]), and individual data are provided in Sup-
plementary Table (see Supplementary Digital Content 5, http://
links.lww.com/AJG/C47). Excluding the patients for whom
SVR12 is unknown, the overall SVR12 rate was 77% (20/26) in
patients with premature treatment discontinuation (8-week G/
P: 5/9; 12-week G/P: 15/17). Reasons for premature discontin-
uation included 16 because of adverse events, 11 noncompliant
with the treatment dosing, 5 lost to follow-up, 3 because of
pregnancy, and 2 on-treatment virologic failures.
DISCUSSION
Optimal adherence to HCV treatment is still perceived to be a key
factor of treatment success by some treatment prescribers, but
emerging data have demonstrated some degree of forgiveness for
today’s highly potent and effective DAA regimens, including G/P
(7,8,16). In general, high adherence to DAA treatment has been
observed in clinical trials (6,7) even in populations that may be
considered at increased risk of nonadherence (8,17). The findings
of these post hoc analyses provide additional evidence on the im-
pact of treatment duration on adherence rates, while also providing
further support for the concept of “treatment forgiveness” with
modern DAA regimens. Although overall adherence rates are
generally high with all-oral DAA regimens, several studies have
now demonstrated that longer treatment durations lead to higher
rates of nonadherence; in particular, nonadherence rates are higher
the further a patient is from treatment initiation (6,7,17,34).
In accordance with our findings, the SYNERGY study showed
a statistically significant decrease in adherence to ledipasvir/
sofosbuvir comparing treatment in weeks 0–4 to weeks 8–12
(98.1% 6 0.9% vs 95.0% 6 1.2%; P 5 0.04) (6). Similarly, the
Figure 3.Details of each G/P treatment interruption for each patient. Each bar represents an individual patient; numbers represent number of days of treatment
interruption; gray bars represent patients with 1 treatment interruption; black bars represent patients with multiple treatment interruptions. Bold text denotes
patientswithmissingSVR12data. *Reasonablepossibility of relationship to studydrug.†Erosive gastritis hada reasonablepossibility of relationship to studydrug.
AE, adverse event; G/P, glecaprevir/pibrentasvir; SVR, sustained virologic response; SVR12, sustained virologic response at post-treatment week 12.
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results of the SIMPLIFY study in patients with recent drug use
receiving SOF/VEL reported statistically significant increased
odds of nonadherence of 8% per week (95% CI 1.06–1.11) over
the course of 12-week therapy (8). This increased nonadherence
to SOF/VEL occurred despite incentivization of patients to return
electronic blister packs. TheANCHOR study in people who inject
drugs receiving 12-week SOF/VEL observed a steady decline in
visit adherence from week 4 (88%) to week 8 (83%) to week 12
(70%). In the same study, medication dispensation also declined
from 97% at week 4–92% at week 8, indicating that 8 of the 100
enrolled patients, at aminimum, did not receive the thirdmonth’s
supply of their 12-week course (17).
In our post hoc analysis ofG/P clinical trials, overall adherencewas
high regardless of treatment duration or cirrhosis status. When ex-
amining consecutive 4-week treatment intervals, a modest, but sta-
tistically significant decline in adherence was observed the longer
patients remained on treatment. Nevertheless, suboptimal adherence
did not compromise SVR12 rates with 8- or 12-week G/P therapy, a
finding consistent with a pooled analysis of ongoing observational
studies of G/P treatment (35). The impact of poor adherence on
efficacy of treatment also seems tobe limited for otherDAAregimens
with high SVR rates reported in both SYNERGY and SIMPLIFY
(6,8). In the ANCHOR study, 100 patients infected with HCV and
ongoing injectiondruguse receiveda12-weekcourseof SOF/VELat a
harm reduction facility. The SVR12 rate (89%, 82/92) was not im-
pacted by suboptimal adherence (P 5 0.35) (17). Adherence is an-
ticipated to be lower in real-world settings than a clinical trial setting
where patients believed to be at risk of nonadherence are often ex-
cluded and in which regular study visits facilitate adherence. None-
theless, SVR rates for G/P in real-world settings remain high (19,20).
In the current study, although high SVR rates were maintained
as duration of treatment increased, there was a significantly in-
creased risk of nonadherence associated with 12-week treatment
compared with 8-week treatment. Interestingly, the current study
did not observe any difference in adherence between patients with
and without compensated cirrhosis. One identified patient factor
associated with nonadherence from our analysis included those
with a history of psychiatric disorder, althoughnotably our analysis
did not identify history of injection drug use or concomitant opioid
agonist therapy as baseline factors associated with nonadherence.
These findings provide further evidence that, although adherence
to G/P treatment is generally high in both 8-week and 12-week reg-
imens, there seems to be some treatment forgiveness. The question
therefore arises whether some patients are being overtreated with an
8-week course of 300/120-mg G/P. Although 8-week durations of
lowerG/Pdoses have not been examined, a dose-rangingphase 2 trial
examining 12 weeks of G/P 200/120 mg or 200/40 mg (GT1/3 only)
observedSVRrates.97% inGT1noncirrhotic patients treated for 12
weeks (36). However, these lower dose combinations had lower ef-
ficacy in GT3-infected patients (SVR12 83%) (36); thus, lower doses
were not studied in phase 3 in order to offer 1 fixed-dose pan-
genotypic combination for all patients. The lack of impact of sub-
optimal adherence to the 12-week duration in this analysis not
surprising in lightof the abilityofG/P toelicit anSVR inmostpatients
with 8 weeks of total treatment, regardless of cirrhosis status (29).
Interruption of G/P treatment was generally rare and typically
did not occur for longer than 2 dayswith no interruptions resulting
in treatment failure. Most G/P interruptions reported were related
toadverse eventsor accidentallymisseddoses. Limited information
is available on the impact of treatment interruption on treatment
efficacy. Missed doses were analyzed as part of the SYNERGY
study, where the authors reported high SVR rates (58/60 patients
[96.6%]) and all patients who missed $2 consecutive doses
achieving SVR (6). The ANCHOR study reported no statistically
significant difference in SVR achieved by patientswith andwithout
treatment interruptions, with ITT SVR12 rates of 75% and 83%,
respectively (17). Although concerns about relapse may exist for
patients who interrupt G/P treatment, these data suggest that
neither timing of missed dose nor duration of interruption are
associated with virologic failure with G/P. Nonetheless, larger data
sets of noncompliance are needed to confirm these findings.
Therewere several limitationsof this study.Thepopulationswere
limitedby the inclusionandexclusioncriteria of the clinical trials and
may not represent the population of patients with HCV in the real
world.Notably, only theENDURANCE-3 trial allowedpatientswith
active illicit drug use or positive urine drug screen at baseline. This
should be considered when comparing these results with adherence
studies conducted in people who use drugs. Another limitation was
the small GT6 population which limits comparisons between ge-
notypes; however, in the logistic regression, GT6 still came out as a
predictor to nonadherence compared with GT1. Although 8-week
and 12-week sample sizes differ and have some imbalance in
patient characteristics that may impact adherence (e.g., history
of injection drug use or psychiatric disorder), the adherence
results for each individual duration and cirrhosis status in-
dicate a consistent trend of increasing nonadherence over time
when there is no imbalance in sample size or patient de-
mographics (see Supplementary Figure, Supplementary Digital
Content 3, http://links.lww.com/AJG/C45). Although the
overall populations were large, the number of patients with
interruptions was low as were the numbers of patients with
extended interruptions; therefore, any conclusions regarding
the outcomes of patients with treatment interruption must be
taken with caution. Furthermore, as adherence was generally
high, the number of patients with nonadherence (,80% or
,90% adherence) was low, especially when analyzed by treat-
ment duration and cirrhosis status. Although nonadherence
did not result in lower SVR rates in this clinical trial analysis,
real-world data are needed to confirm this observation.
This study provides evidence that should reassure prescribers
that suboptimal treatment adherence or treatment interruption does
not compromise SVR12 rates, evenwith the shortest duration ofG/P
treatment. These data may be especially useful when considering
HCV treatment in patients at risk of nonadherence, supporting the
use of G/P in patients that historicallymay have been excluded from
treatment because of fears of nonadherence (7,15,21). Overall, these
findings support efforts to improve access to treatment for all pa-
tients with HCV infection, including those with risk factors for poor
adherence. It is anticipated that these data may help to simplify the
HCV care pathway and help achieve the World Health Organiza-
tion’s goal of HCV elimination by 2030 (18).
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